Evidence map›Paper›PMID 34926469›Full record

ArticleFrontiers in cell and developmental biology2021

Notoginsenoside R1 Protects Against High Glucose-Induced Cell Injury Through AMPK/Nrf2 and Downstream HO-1 Signaling.

Fawang Du, Huiling Huang, Yalin Cao, Yan Ran, Qiang Wu, Baolin Chen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Frontiers in pharmacology · 2026
    Article
  3. Article
  4. Erianin mitigates diabetic cardiomyopathyWorld journal of diabetes · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fawang DuDepartment of Cardiology, Guizhou Provincial People's Hospital, Guiyang, China.
Huiling HuangDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Yalin CaoDepartment of Cardiology, Guizhou Provincial People's Hospital, Guiyang, China.
Yan RanDepartment of Nephrology, Guizhou Provincial People's Hospital, Guiyang, China.
Qiang WuDepartment of Cardiology, Guizhou Provincial People's Hospital, Guiyang, China.
Baolin ChenNanmingtang Clinic, Guizhou Provincial People's Hospital, Guiyang, China.
Guizhou Provincial People's Hospital · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Notoginsenoside R1 (NGR1), the primary bioactive compound found in Panax notoginseng, is believed to have antihypertrophic and antiapoptotic properties, and has long been used to prevent and treat cardiovascular diseases. However, its potential role in prevention of diabetic cardiomyopathy remains unclear. The present study aimed to investigate the mechanism of NGR1 action in high glucose-induced cell injury. H9c2 cardiomyocytes were cultured in a high-glucose medium as an

Indexed as

AMPKapoptosisdiabetic cardiomyopathyhigh glucose-induced cell injurynotoginsenoside R1Nrf2

Identifiers

PMID34926469
PMCPMC8672164
OpenAlexW3216854925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.